Close
4

Athena Athena

X

Company profile for EmphyCorp

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
EmphyCorp has been granted eight U.S. patents and three additional are pending with respect to its new drug, "N115". Until now the primary treatment for asthmatic bronchitis and chronic obstructive pulmonary diseases is the use of corticosteroids (67%). It is well documented that prolonged use of corticosteroids for the treatment of pulmonary diseases has serious side effects including death. Other marketed drugs for the treat...
EmphyCorp has been granted eight U.S. patents and three additional are pending with respect to its new drug, "N115". Until now the primary treatment for asthmatic bronchitis and chronic obstructive pulmonary diseases is the use of corticosteroids (67%). It is well documented that prolonged use of corticosteroids for the treatment of pulmonary diseases has serious side effects including death. Other marketed drugs for the treatment of pulmonary diseases can produce central nervous system, cardiovascular, respiratory and gastrointestinal problems.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
EmphyCorp
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
84 Park Avenue Flemington, NJ 08822 United States
Telephone
Telephone
1-908-237-1561
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY